prevnar 13 came on the market in 2003.
prevnar 13 came on the market in 2003.
when did prevnar 13 come on the market?
2003
bullet::::- prevnar 13 (pcv13) is produced by pfizer. it is a tridecavalent vaccine, meaning that it contains thirteen serotypes of pneumococcus (1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f) which are conjugated to diphtheria carrier protein. prevnar 13 was approved by the u.s. food and drug administration on february 24, 2010. after waiting for the outcome of a trial underway in the netherlands, the centers for disease control and prevention (cdc) recommended the vaccine for adults over age 65 in august 2014.









































section::::production technique.









































section::::production technique.:prevnar.
pneumococcal conjugate vaccine
children under the age of two years fail to mount an adequate response to the 23-valent adult vaccine, and instead a 13-valent pneumococcal conjugated vaccine (pcv) (e.g. prevnar 13) must be used. prevnar 13 is a new vaccine which has replaced prevnar 7, adding six new serotypes to the vaccine. while this covers only thirteen strains out of more than ninety strains, these thirteen strains caused 80 percent to 90 percent of cases of severe pneumococcal disease in the us before introduction of the vaccine, and it is considered to be nearly 100 percent effective against these strains.
pneumococcal polysaccharide vaccine